Malignant infantile osteopetrosis

Editor-In-Chief: Prab R Tumpati, MD
Obesity, Sleep & Internal medicine
Founder, WikiMD Wellnesspedia &
W8MD's weight loss doctor NYC
Philadelphia GLP-1 weight loss and GLP-1 clinic NYC
| Malignant infantile osteopetrosis | |
|---|---|
| Synonyms | Albers-Schönberg disease, marble bone disease |
| Pronounce | N/A |
| Specialty | Hematology, Orthopedics |
| Symptoms | Bone pain, Fractures, Anemia, Hepatosplenomegaly, Blindness, Deafness |
| Complications | Bone marrow failure, Infections, Neurological deficits |
| Onset | Infancy |
| Duration | Lifelong |
| Types | N/A |
| Causes | Genetic mutation |
| Risks | Family history |
| Diagnosis | X-ray, Genetic testing |
| Differential diagnosis | Osteoporosis, Rickets, Paget's disease of bone |
| Prevention | N/A |
| Treatment | Hematopoietic stem cell transplantation, Interferon gamma-1b, Vitamin D |
| Medication | N/A |
| Prognosis | Poor without treatment |
| Frequency | Rare |
| Deaths | N/A |
Malignant Infantile Osteopetrosis (MIOP), also known as infantile malignant osteopetrosis, is a rare, severe bone disorder that manifests early in infancy. It is characterized by the excessive formation and density of bone, which leads to a variety of complications. This condition is a form of osteopetrosis, a group of disorders affecting bone growth and density. MIOP is considered the most severe form of osteopetrosis and is inherited in an autosomal recessive manner.
Etiology and Pathogenesis[edit]
Malignant Infantile Osteopetrosis is caused by mutations in several genes, including TCIRG1, CLCN7, and OSTM1, which are crucial for the normal function of osteoclasts. Osteoclasts are cells responsible for bone resorption, a process essential for the maintenance of healthy bone tissue. Mutations in these genes lead to dysfunctional osteoclasts, resulting in the abnormal accumulation of bone and the hallmark feature of osteopetrosis: increased bone density.
Clinical Features[edit]
The clinical manifestations of MIOP are diverse and can include:
- Failure to thrive
- Hepatosplenomegaly (enlargement of the liver and spleen)
- Cranial nerve deficits leading to vision and hearing loss
- Hydrocephalus (accumulation of cerebrospinal fluid in the brain)
- Frequent bone fractures
- Anemia and other hematologic abnormalities due to bone marrow failure
Diagnosis[edit]
Diagnosis of Malignant Infantile Osteopetrosis is based on clinical presentation, radiographic findings, and genetic testing. Radiographs typically show generalized increased bone density, particularly at the skull base and long bones. Genetic testing can confirm the diagnosis by identifying mutations in the genes associated with the condition.
Treatment[edit]
Treatment options for MIOP are limited and focus on managing symptoms and complications. Current therapies include:
- Bone marrow transplantation (BMT), which can cure the bone marrow failure and correct some of the skeletal abnormalities
- Interferon gamma-1b therapy, which has been shown to improve white blood cell function and increase bone resorption
- Supportive care for complications such as anemia, fractures, and cranial nerve deficits
Prognosis[edit]
The prognosis for untreated Malignant Infantile Osteopetrosis is poor, with most affected children not surviving past early childhood due to complications such as bone marrow failure and infections. However, successful bone marrow transplantation can significantly improve life expectancy and quality of life.
Epidemiology[edit]
Malignant Infantile Osteopetrosis is a rare disorder, with an estimated incidence of 1 in 250,000 to 300,000 live births worldwide. It affects males and females equally.
See Also[edit]
Sponsored Health Resource

W8MD Weight Loss, Sleep & MedSpa
Looking for physician-supervised weight loss, semaglutide, tirzepatide, or GLP-1 receptor agonist options? W8MD helps eligible patients in New York City, Brooklyn, New Jersey, Connecticut, Pennsylvania, Delaware, and greater Philadelphia with medical weight loss, sleep medicine, and long-term maintenance support.
GLP-1 specials: Affordable GLP-1 injections NYC and Philadelphia starting from $29.99/week and up for semaglutide with insurance accepted for qualifying visits, and $45/week and up for tirzepatide with insurance accepted for qualifying visits. Self-pay options start from $59.99/week and up for semaglutide and $69.99/week and up for tirzepatide.
- Medical weight loss NYC
- Affordable GLP-1 injections NYC
- Budget GLP-1 weight loss shots Philadelphia
- New Jersey medical weight loss
- NYC medical weight loss blog
- Philadelphia weight loss blog
- Sleep medicine and sleep apnea services
- W8MD MedSpa and wellness
Book a W8MD appointment · View GLP-1 specials
Paid promotional message. Eligibility, pricing, insurance coverage, medication availability, and results vary. Medical evaluation required.
Medical Disclaimer: WikiMD is for informational purposes only and is not a substitute for professional medical advice. Content may be inaccurate or outdated and should not be used for diagnosis or treatment. Always consult your healthcare provider for medical decisions. Verify information with trusted sources such as CDC.gov and NIH.gov. By using this site, you agree that WikiMD is not liable for any outcomes related to its content. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Translate page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian